FLT3 and acute myeloid leukemia: In the frontline setting, the phase 3 QuANTUM-FIRST (NCT02668653) trial [140] enrolled patients up to age 75 with ND AML and FLT3-ITD and randomized them to QUIZ or placebo in addition to induction therapy with 7 + 3.